Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study

Guo, Na; Peng, Zhilan

doi:10.1186/s13048-017-0310-y

Cited by 31 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the CA125 level exceeds 10 U/ml and continuously increases, it needs to be vigilantly monitored and combined with an imaging examination (PET-CT). [8] This is exactly what happened in our case.…”

Section: Discussionsupporting

confidence: 83%

Brain metastasis from ovarian clear cell carcinoma

Liu

Feng

et al. 2019

Medicine

View full text Add to dashboard Cite

Rationale:Epithelial ovarian carcinoma (EOC) is the most common type of ovarian carcinoma, and the leading cause of female genital tract cancer-related deaths. However, brain metastasis (BM) of EOC is rare, with an incidence of only 1% to 2%. Ovarian clear cell carcinoma (OCCC), accounting for 5% to 25% of all EOC cases, has a poor prognosis compared with other epithelial cell type carcinomas.Patient concerns:We retrospectively analyzed the clinical data of a 62-year-old female, who was hospitalized with the main complaint of BM detection for 1 month. She was first diagnosed with ovarian cancer in 2004, and underwent a left oophorectomy. Three years later, the cancer metastasized to the other side, and she underwent a right oophorectomy, followed by 7 courses of platinum-based chemotherapy. She received regular follow-up, and tumor markers and pelvic imaging did not show any signs of progression until July 2012.Diagnosis:Combining the clinical manifestations with the results of radiological and pathological examinations, the findings were consistent with a diagnosis of BM from OCCC.Interventions:She received more than 20 courses of chemotherapy since July 2012. The BM was detected in 2016, and she underwent an intracranial lesion resection.Outcomes:Unfortunately, the patient went into a coma after the surgery, and passed away 1 month later.Lessons:For early detection of BM in long-term ovarian cancer, emphasis should be placed on the patient's neurological symptoms and signs as well as serum tumor marker changes. The combination of surgery, radiology, and chemotherapy may achieve long overall survival.

show abstract

Section: Discussionsupporting

confidence: 83%

Brain metastasis from ovarian clear cell carcinoma

Liu

Feng

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…However, the sensitivity of CA-125 tests for levels >35 U/ml, which indicates a diagnosis of recurrence in ovarian cancer, is below 70%. [3,4] The low sensitivity of CA-125 tests may be because the levels of antigen from small recurrent tumors may be too low to activate an antibody response. Therefore, CA-125 tests and CT are not useful for predicting prognosis immediately after debulking surgery, and the identification of new biomarkers reflecting current disease activity is urgently needed for ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer

et al. 2019

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) have received enormous attention as a novel biomarker in various malignant diseases. We investigated the clinical association between the presence of perioperative CTCs and survival outcomes in women with ovarian cancer. In a total of 30 women who were scheduled to undergo a surgical treatment for ovarian cancer, peripheral blood samples were obtained before and after surgery. CTCs were isolated and counted using the optimized tapered-slit filter (TSF) platform. The association between the presence of perioperative CTCs and tumor features was evaluated. The impact of the presence of perioperative CTCs on progression-free survival (PFS) and overall survival (OS) rates were analyzed using a Kaplan–Meier method. The median age was 58 (range, 24–77) years, and the median follow-up period was 31.5 (range, 1–41) months. Overall, the CTC detection rate was not significantly different before and after surgery (76.7% vs 57.1%, P = .673). The presence of postoperative CTCs was not significantly associated with 3-year PFS (29.1% vs 58.3%, P = .130) and OS (84.4% vs 80.0%, P = .559) rates in the whole study population. In advanced stage, PFS rate in patients with postoperative CTCs had lower PFS rates than those without postoperative CTCs, although there was no statistical significance (18.8% vs 57.1%, P = .077). Postoperative CTC was more frequently detected in women who had lymph node involvement than those who did not (7/7 [100%] vs 3/10 [30.0%], P = .010). The presence of postoperative CTCs as detected using the TSF platform seems to be associated with poorer PFS rates in women with ovarian cancer of advanced stage. Further study with a larger population is warranted to validate our study findings.

show abstract

“…Other tumor markers, such as CA125, human epididymis protein (HE4) can be used. A value of CA125 between 10 and 35 U/mL indicates a relative risk of recurrence for postoperative patients of epithelial ovarian carcinoma (15), while the rising HE4 value can predict recurrent epithelial ovarian cancer with specificity of 95.6%, and a sensitivity of 52.7%. However, in our case, the values of CA125 and HE4 were always normal.…”

Section: Discussionmentioning

confidence: 99%